Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
Full Data Readout Expected in the Second Half of.
Biotechnology company NeuroBo Pharmaceuticals, Inc. (NRBO) announced Wednesday the receipt of Safety Review Committee (SRC) approval, recommending that the two-part Phase 2a trial of DA-1241 can continue without modification following a blinded safety review of the first six months of study conduct.
Biotechnology company NeuroBo Pharmaceuticals, Inc. (NRBO), Thursday announced that it has received first site Institutional Review Board or IRB approval for Alexander Prezioso, Investigator, Clinical Pharmacology of Miami, to proceed with the Phase 1 clinical trial of DA-1726 for the treatment of obesity.
NeuroBo Pharmaceuticals (NRBO) Receives First Site IRB Approval for Its Phase 1 Trial of DA-1726 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today.